Nanne Kleefstra
Research Subjects
Nanne Kleefstra has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Angela H. E. M. Maas
Cardiology for Women, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication - Corine Ekhart
Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH ’s-Hertogenbosch, The Netherlands
1 shared publication - Eugène P. van Puijenbroek
Groningen Research Institute of Pharmacy, Pharmacotherapy, -Epidemiology and -Economics, University of Groningen, Groningen, The Netherlands
1 shared publication - Henk J. G. Bilo
Department of Internal Medicine, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands
1 shared publication Jako S. Burgers
Dutch College of General Practitioners, Utrecht, The Netherlands
1 shared publication- Klaas H. Groenier
Diabetes Centre, Isala, Zwolle, The Netherlands
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 2 April 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (7) , 1507-1515
Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
Aims: We aimed to assess and characterize sex differences in adverse drug reactions (ADRs) reported to the national pharmacovigilance centre in the Netherlands while considering differences in drug use.Methods: ADRs spontaneously reported by healthcare professionals and patients to the Netherlands pharmacovigilance centre Lareb were used. Drug–ADR combinations reported at least 10 times between 2003–2016 for drugs used by ≥10,000 persons in that period were included. Data about the number of drug users was obtained from the National Health Care Institute. Sex‐specific ADRs, like gynaecological problems, were excluded. Sex differences in specific drug–ADR combinations were tested using bivariate logistic regression analyses in which the number of drug users per sex was taken into account.Results: In total, 2483 drug–ADR combinations were analysed. Possibly relevant sex differences were shown in 363 combinations (15%). Most of these drug–ADR combinations were reported more often for women (322 combinations). Drugs with the highest number of ADRs that were more often reported for women included thyroid hormones (32 combinations) and antidepressants (16 combinations for the centrally acting sympathomimetics; 14 combinations for other antidepressants). Some ADRs were predominantly reported for women across a range of drugs such as headache and dizziness whereas other ADRs such as tendon ruptures and aggression were reported more often for men.Conclusions: Identified sex differences in reported ADRs often referred to women. These differences may have various causes, including pharmacological and behavioural causes, which need to be further assessed. The results may ultimately lead to sex‐specific prescribing or monitoring recommendations.
- 2 April 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (7) , 1507-1515
Top Cited PapersOpen AccessSex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
Aims: We aimed to assess and characterize sex differences in adverse drug reactions (ADRs) reported to the national pharmacovigilance centre in the Netherlands while considering differences in drug use.Methods: ADRs spontaneously reported by healthcare professionals and patients to the Netherlands pharmacovigilance centre Lareb were used. Drug–ADR combinations reported at least 10 times between 2003–2016 for drugs used by ≥10,000 persons in that period were included. Data about the number of drug users was obtained from the National Health Care Institute. Sex‐specific ADRs, like gynaecological problems, were excluded. Sex differences in specific drug–ADR combinations were tested using bivariate logistic regression analyses in which the number of drug users per sex was taken into account.Results: In total, 2483 drug–ADR combinations were analysed. Possibly relevant sex differences were shown in 363 combinations (15%). Most of these drug–ADR combinations were reported more often for women (322 combinations). Drugs with the highest number of ADRs that were more often reported for women included thyroid hormones (32 combinations) and antidepressants (16 combinations for the centrally acting sympathomimetics; 14 combinations for other antidepressants). Some ADRs were predominantly reported for women across a range of drugs such as headache and dizziness whereas other ADRs such as tendon ruptures and aggression were reported more often for men.Conclusions: Identified sex differences in reported ADRs often referred to women. These differences may have various causes, including pharmacological and behavioural causes, which need to be further assessed. The results may ultimately lead to sex‐specific prescribing or monitoring recommendations.
- Open Access
- 30 August 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-8
Patient Activation in Type 2 Diabetes: Does It Differ between Men and Women?
Background.Aim was to investigate whether the degree of patient activation of patients with type 2 diabetes (T2D) is different between men and women. Furthermore, we investigated which factors are associated with patient activation in men and women.Methods.This cross-sectional study included 1615 patients with T2D from general practices. Patient activation was measured with the Patient Activation Measure (PAM) questionnaire. Multivariate linear regression analyses were used to investigate the association between gender and patient activation. Stratified analyses according to gender were performed to investigate which factors are associated with patient activation.Results.No association between gender and PAM score was found after adjustment for all selected confounders (). In men, lower age (), a higher WHO-5 score (), and a lower BMI () were associated with a higher PAM score. In women, a higher WHO-5 score () and the absence of macrovascular complications () were associated with a higher PAM score.Conclusion.There is no difference in the degree of patient activation of men and women with T2D. Age, well-being, and BMI were found to be associated with patient activation in men, whereas well-being and macrovascular complications were found to be associated with patient activation in women.- 30 August 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-8
Open AccessPatient Activation in Type 2 Diabetes: Does It Differ between Men and Women?
Background.Aim was to investigate whether the degree of patient activation of patients with type 2 diabetes (T2D) is different between men and women. Furthermore, we investigated which factors are associated with patient activation in men and women.Methods.This cross-sectional study included 1615 patients with T2D from general practices. Patient activation was measured with the Patient Activation Measure (PAM) questionnaire. Multivariate linear regression analyses were used to investigate the association between gender and patient activation. Stratified analyses according to gender were performed to investigate which factors are associated with patient activation.Results.No association between gender and PAM score was found after adjustment for all selected confounders (). In men, lower age (), a higher WHO-5 score (), and a lower BMI () were associated with a higher PAM score. In women, a higher WHO-5 score () and the absence of macrovascular complications () were associated with a higher PAM score.Conclusion.There is no difference in the degree of patient activation of men and women with T2D. Age, well-being, and BMI were found to be associated with patient activation in men, whereas well-being and macrovascular complications were found to be associated with patient activation in women.